VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that two abstracts featuring data from the Phase 3 program evaluating Sci-B-Vac®, the company’s tri-antigenic prophylactic hepatitis B (HBV) vaccine, have been accepted for presentation at The Digital International Liver CongressTM 2020 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place on August 27-29, 2020. The presentations will include a late-breaker oral presentation and a poster presentation, which has been selected for a poster tour.

The presentation details and schedules are as follows:

Late-Breaker Oral Presentation

  • Abstract #: AS169
  • Title: High HBsAb titers consistent across 3 lots of the tri-antigenic HepB Vaccine, Sci-B-Vac®: Results from the second pivotal Phase 3 double-blind, randomized controlled trial designed to assess the lot-to-lot consistency of Sci-B-Vac® in adults (CONSTANT)
  • Session: Abstract Session: HBV – Clinical
  • Date: Saturday, August 29, 2020
  • Time: 12:15 – 12:30 CEST
  • Presenter: Adam Finn, M.D., Ph.D., Professor of Paediatrics at the University of Bristol, UK, and principal investigator of the CONSTANT Phase 3 clinical study
  • Event Website: https://ilc-congress.eu/

The oral presentation will be displayed as a 10-minute pre-recorded video followed by a five-minute live Q&A session.

Poster Presentation

  • Abstract #: 1181
  • Title: Higher proportion of responders with Hepatitis B Antibody levels ≥ 100 mIU/mL with the tri-antigenic HepB vaccine, Sci-B-Vac®, compared to Engerix-B®: Results from the phase 3 double-blind, randomized study comparing immunogenicity and safety (PROTECT)
  • Session: Poster tour: Viral Hepatitis A, B, C, D, E: Immunology
  • Date: Thursday, August 27, 2020
  • Time: 12:30 – 13:00 CEST
  • Presenter: Timo Vesikari, M.D., Ph.D., Professor Emeritus and Director of the Northern Vaccine Research Network in Finland, and principal investigator of the PROTECT and CONSTANT Phase 3 clinical studies
  • Event Website: https://ilc-congress.eu/

Dr. Vesikari will give a live presentation of the poster during the Poster Tour, followed by a three-minute live Q&A session. A five-minute pre-recorded explanation of the poster will also be available on-demand at the Event Website link above.